tetano
Editor, Senior Moderator
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Aug 10;39(8):1051-1059. doi: 10.3760/cma.j.issn.0254-6450.2018.08.008.
[h=1][Perspectives of antiviral drugs used on influenza].[/h] [Article in Chinese; Abstract available in Chinese from the publisher]
Wang YM[SUP]1[/SUP], Cao B.
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
Antiviral drugs on influenza are important in the control program of influenza. Options for influenza treatment are currently limited to using the neuraminidase inhibitors (NAIs). Given limited effectiveness of NAIs and related resistance, there remains an urgent need for the development of influenza antiviral drugs that can improve the efficacy and provide low propensity of viral resistance. Several influenza-related antiviral drugs that are currently under the late-stage clinical trials all appear differently in the mechanism of action. It is hoped that when new antiviral drugs are licensed, care and outcomes of severe influenza cases will be improved.
[h=4]KEYWORDS:[/h] Antiviral agent; Influenza; Neuraminidase inhibitors; Therapy
PMID: 30180427
[h=1][Perspectives of antiviral drugs used on influenza].[/h] [Article in Chinese; Abstract available in Chinese from the publisher]
Wang YM[SUP]1[/SUP], Cao B.
[h=3]Author information[/h]
[h=3]Abstract[/h] in English, Chinese
Antiviral drugs on influenza are important in the control program of influenza. Options for influenza treatment are currently limited to using the neuraminidase inhibitors (NAIs). Given limited effectiveness of NAIs and related resistance, there remains an urgent need for the development of influenza antiviral drugs that can improve the efficacy and provide low propensity of viral resistance. Several influenza-related antiviral drugs that are currently under the late-stage clinical trials all appear differently in the mechanism of action. It is hoped that when new antiviral drugs are licensed, care and outcomes of severe influenza cases will be improved.
[h=4]KEYWORDS:[/h] Antiviral agent; Influenza; Neuraminidase inhibitors; Therapy
PMID: 30180427